Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells

Molecular Medicine Reports

Volumn 6, Issue 6, 2012, Pages 1355-1360

  Yao, Ruyong ^a   Sui, Aihua ^a   Wang, Zhenli ^b   Liu, Shihai ^a   Zhou, Quan ^a   Liu, Xiangping ^a   Zhang, Haiping ^a  

^a QINGDAO UNIVERSITY   (China)

^b First Sanatorium of Jinan Military District ^*  (China)

Author keywords

Antitumor; Integrin; Lung tumor; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; HOE 33342; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VITRONECTIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CELL ADHESION; CELL VIABILITY; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TUMOR CELL; WESTERN BLOTTING; WOUND HEALING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; ESCHERICHIA COLI; HUMANS; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; OLIGOPEPTIDES; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, VITRONECTIN; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

ESCHERICHIA COLI;

EID: 84868576922     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1071     Document Type: Article

References (19)

1. Travis WD: Pathology of lung cancer. Clin Chest Med 23: 65-81, 2002.
2. Zaba O, Grohe C and Merk J: Novel therapies in non-small cell lung cancer. Minerva Chir 66: 235-244, 2011.
3. Call JA, Eckhardt SG and Camidge DR: Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 9: 1002-1011, 2008.
4. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999. (Pubitemid 29068521)
5. Amm HM, Oliver PG, Lee CH, Li Y and Buchsbaum DJ: Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 11: 431-449, 2011.
6. Szliszka E and Krol W: The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J Cancer Prev 20: 63-69, 2011.
7. Voelkel-Johnson C: TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol 8: 417-427, 2011.
8. Sadarangani A, Kato S, Espinoza N, et al: TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 12: 73-85, 2007. (Pubitemid 46009505)
9. Dyer MJ, MacFarlane M and Cohen GM: Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 25: 4505-4506, 2007. (Pubitemid 350013865)
10. Liu S: Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 3: 472-487, 2006.
11. Falcioni R, Cimino L, Gentileschi MP, et al: Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. Exp Cell Res 210: 113-122, 1994.
12. Kumar CC: Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4: 123-131, 2003.
13. Zitzmann S, Ehemann V and Schwab M: Arginine-glycineaspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 62: 5139-5143, 2002. (Pubitemid 35024582)
14. Buckley CD, Pilling D, Henriquez NV, et al: RGD peptides induce apoptosis by direct caspase-3 activation. Nature 397: 534-539, 1999.
15. Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161: 2833-2840, 1998. (Pubitemid 28425704)
16. Schneider P, Thome M, Burns K, et al: TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7: 831-836, 1997. (Pubitemid 28064896)
17. Pan G, O'Rourke K, Chinnaiyan AM, et al: The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113, 1997. (Pubitemid 27161256)
18. Walczak H, Degli-Esposti MA, Johnson RS, et al: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16: 5386-5397, 1997. (Pubitemid 27380146)
19. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB and Stupp R: Cilengitide: an RGD pentapeptide αvβ3 and αvβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 7: 339-354, 2011.